Circio Holding ASA (OSL:CRNA)
Norway · Delayed Price · Currency is NOK 8.61
-0.29 (-3.26%)
May 28, 2026, 4:29 PM CET
Circio Holding ASA Company Description
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy.
The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells.
It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy.
The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023.
Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.
Circio Holding ASA
| Country | Norway |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Erik Wiklund |
Contact Details
Address: Tordenskiolds gate 2 Oslo, 0160 Norway | |
| Phone | 47 929 51 788 |
| Website | circio.com |
Stock Details
| Ticker Symbol | CRNA |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0013033795 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Erik Digman Wiklund | Chief Executive Officer |
| Dr. Lubor Gaal Ph.D. | Chief Financial Officer |
| Ola Melin | Chief Operating Officer |
| Dr. Thomas Birkballe Hansen | Chief Technology Officer |
| Dr. Victor Levitsky M.D., Ph.D. | Chief Scientific Officer |
| Jon Amund Eriksen M.Sc. | Special Advisor |
| Prof. Gustav Gaudernack Ph.D. | Chief Scientific Adviser |
| Dr. Peter Skorpil Ph.D. | Vice President of Business Development |